AI model for detecting ocular disease using retinal images

Artificial intelligence (AI) models have been validated for recognizing signs of eye diseases in retinal images, enhancing diagnosis, and risk stratification. Combining natural images and medical data, these models provide reliable disease prediction, thereby enabling efficient risk stratification in fields like chest X-rays and dermatology imaging.

In a recent study published in Nature, researchers present retinal image foundation model (RETFound), a self-supervised learning (SSL) masked autoencoder-based foundation model for retinal images. RETFound learns generalizable representations from unlabeled retinal images, which served as the foundation for label-efficient model adaption in various applications.

Study: A foundation model for generalizable disease detection from retinal images. Image Credit: GeebShot / Shutterstock.com

About the study

RETFound is a SSL model that was trained on 1.6 million unlabeled retinal images. An improved SSL-based approach was used on natural images and retinal images retrieved from the Moorfields diabetic image dataset (MEH-MIDAS) with population data to develop two separate models.

MEH-MIDAS is a retrospective dataset containing the full ocular imaging records of 37,401 diabetic patients examined at Moorfields Eye Hospital between January 2000 and March 2022. RETFound was fine-tuned with task labels before verifying its performance on a range of difficult detection and prediction tasks.

Ocular illness diagnostic categorization, prognosis, and oculomic problems including the three-year estimation of cardiovascular disorders like myocardial infarction, cardiac failure, and ischemic stroke, and neurodegenerative disease like Parkinson's disease, were assessed. The illness-detection ability of RETfound was investigated using variable-controlling tests and qualitative findings, whereas its performance and generalizability in adjusting to varied ocular activities after pretraining on retinal scans were examined.

RETFound was tested using diabetic retinopathy databases of MESSIDOR-2, the Indian diabetic retinopathy image (IDRID), and Kaggle APTOS-2019, which were classified according to the International Clinical Diabetic Retinopathy Severity scale. Cross-evaluation was performed between the three databases and models were fine-tuned using a single dataset before being tested on the other ones.

The internal performance of AlzEye data was determined for the one-year prognosis of another eye transitioning to wet macular degeneration. Four oculomic challenges were devised to assess the effectiveness of the model in predicting the occurrence of systemic disorders using retinal scans.

RETFound was trained to detect general structural abnormalities for the diagnosis of systemic disorders.

Study findings

With fewer labeled data, the Adapted RETFound model regularly surpassed many comparator models in the diagnosis and prognosis of sight-threatening eye illnesses, as well as the incident prediction of complicated systemic ailments including heart failure and myocardial infarction. As compared to state-of-the-art rival models, including those pre-trained on ImageNet-21k using classical transfer learning, RETFound consistently outperformed these models in terms of its performance and label efficiency.

The most prominent imaged areas reflected existing information from ocular and oculomic literature. In most datasets, RETFound performed the best, followed by SL-ImageNet.

On the MESSIDOR-2, IDRID, and Kaggle APTOS-2019, datasets, RETFound obtained area under the receiver operating curve (AUROC) values of 0.9, 0.8, and 0.9, respectively, which significantly surpassed SL-ImageNet.

Superior performance was also observed in categorizing several illnesses such as glaucoma. The findings of RETFound AUPR were similarly considerably higher than those of the comparable groups.

In terms of the prognosis of ocular diseases, RETFound outperformed the comparator groups considerably, with an AUROC value of 0.9. RETFound had the greatest AUROC value of 0.8 using color fundus photography (CFP) as the input modality, which was significantly higher as compared to SSL-Retinal. Furthermore, the RETFound AUPR scores were greatest with color fundus photographs and equivalent to the SSL-Retinal model using optical coherence tomography (OCT).

RETFound had an AUROC value of 0.7 for predicting myocardial infarctions using color fundus photographs, whereas SSL-Retinal ranked second but was considerably poorer than RETFound. RETFound also outperformed the other AI models considering OCT images as inputs imaging modality.

RETFound demonstrated improved label efficiency across many tasks, thus highlighting the potential utility of this approach to ease data shortages. Consistently good adaptation efficiency was also observed, which implies that RETFound required less time to adjust to downstream tasks. RETFound discovered and inferred the representation of illness-related regions using SSL for eye disease detection, thereby contributing to performance and label efficiency in downstream operations.

Anatomical structures related to systemic disorders were highlighted as regions contributing to the prediction of incidences of systemic disorders in oculomic tasks. RETFound maintained consistent performance, even when the age difference was reduced, thus demonstrating that this model detected disease-related anatomical structural changes and utilized the data to forecast systemic disorders.  

Conclusions

RETFound is a generalizable method for increasing retinal imaging performance and strengthening AI applications' diagnostic and prognostic capabilities. This model employs SSL on unlabeled and natural retinal images, thereby exceeding the strong SL-ImageNet and improving the overall performance of medical foundation models.

Journal reference:
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2023, September 18). AI model for detecting ocular disease using retinal images. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20230918/AI-model-for-detecting-ocular-disease-using-retinal-images.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "AI model for detecting ocular disease using retinal images". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20230918/AI-model-for-detecting-ocular-disease-using-retinal-images.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "AI model for detecting ocular disease using retinal images". News-Medical. https://www.news-medical.net/news/20230918/AI-model-for-detecting-ocular-disease-using-retinal-images.aspx. (accessed October 07, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2023. AI model for detecting ocular disease using retinal images. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20230918/AI-model-for-detecting-ocular-disease-using-retinal-images.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Enhancing patient outcomes with AI-driven intratumoral immunotherapy